OPEN ACCESS

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Gillian Ellison,¹ Guanshan Zhu,² Alexandros Moulis,³ Simon Dearden,¹ Georgina Speake,¹ Rose McCormack¹

¹AstraZeneca, Macclesfield, Alderley Park, UK

²AstraZeneca R&D, Shanghai, China

³AstraZeneca SA Hellas, Athens, Greece

Correspondence to

Dr Gillian Ellison, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK; gillian.ellison@astrazeneca.com

Received 10 September 2012

Revised 19 October 2012

Accepted 22 October 2012

Published Online First

20 November 2012

ABSTRACT

Aims Activating mutations in the gene encoding epidermal growth factor receptor (EGFR) can confer sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib in patients with advanced non-small-cell lung cancer. Testing for mutations in *EGFR* is therefore an important step in the treatment-decision pathway. We reviewed reported methods for *EGFR* mutation testing in patients with lung cancer, initially focusing on studies involving standard tumour tissue samples. We also evaluated data on the use of cytology samples in order to determine their suitability for *EGFR* mutation analysis.

Methods We searched the MEDLINE database for studies reporting on *EGFR* mutation testing methods in patients with lung cancer.

Results Various methods have been investigated as potential alternatives to the historical standard for *EGFR* mutation testing, direct DNA sequencing. Many of these are targeted methods that specifically detect the most common *EGFR* mutations. The development of targeted mutation testing methods and commercially available test kits has enabled sensitive, rapid and robust analysis of clinical samples. The use of screening methods, subsequent to sample micro dissection, has also ensured that identification of more rare, uncommon mutations is now feasible. Cytology samples including fine needle aspirate and pleural effusion can be used successfully to determine *EGFR* mutation status provided that sensitive testing methods are employed.

Conclusions Several different testing methods offer a more sensitive alternative to direct sequencing for the detection of common *EGFR* mutations. Evidence published to date suggests cytology samples are viable alternatives for mutation testing when tumour tissue samples are not available.

INTRODUCTION

Lung cancer is the most frequently diagnosed of all cancers and is responsible for approximately 1.38 million deaths each year worldwide.¹ Non-small-cell lung cancer (NSCLC) is the most common form of lung cancer and first-line treatment of advanced NSCLC often involves platinum-based combination chemotherapy.² However, for patients with advanced NSCLC harbouring an activating mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR), targeted treatment is available in the form of the EGFR TK inhibitors (TKIs) gefitinib and erlotinib.

Activating somatic mutations in the *EGFR* gene conferring sensitivity to EGFR TKIs were first reported in 2004.^{3–5} Since then, the efficacy of

first-line gefitinib and erlotinib in patients with EGFR mutation-positive advanced NSCLC has been demonstrated in a number of Phase III trials.^{6–11} In the Iressa Pan-Asia Study, progression-free survival (PFS) was significantly longer with gefitinib than carboplatin/paclitaxel for patients whose tumours harboured activating EGFR mutations. In patients with wild-type EGFR, carboplatin/paclitaxel was associated with significantly longer PFS than gefitinib.⁸ The conformational change seen in the TK domain of mutated EGFRs increases the activation of the domain and its affinity for ATP (and EGFR TKIs) compared with wild-type EGFR.³ The resulting increase in binding of EGFR TKIs produces greater inhibition of the domain and blocking of signal transduction pathways implicated in the proliferation and survival of cancer cells. Gefitinib also improved PFS versus chemotherapy in two Phase III trials performed solely in patients with EGFR mutation-positive advanced NSCLC.^{6–7} In addition, in two Phase III erlotinib trials that recruited EGFR mutation-positive patients, PFS was significantly increased with first-line erlotinib relative to chemotherapy.^{9–10} As a result of these data, the accurate identification of patients who might benefit from EGFR TKI therapy has become an important step in the treatment-decision pathway for advanced NSCLC.^{9–12}

Mutations associated with enhanced sensitivity to EGFR TKIs are found in exons 18–21 of the TK domain of EGFR.^{3–4} Two types of mutation—short in-frame deletions in exon 19, clustered around the amino-acid residues 747–750 and a specific exon 21 point mutation (L858R)—have been reported to comprise up to 90% of all activating EGFR mutations.^{3–4–13} Other activating mutations include point mutations in exon 18 (including mutations in codon 719) and point mutations and in-frame insertions in exon 20 (including T790M). The prevalence of EGFR mutations differs according to ethnicity; approximately 10–12% of non-Asian patients with advanced NSCLC harbour these mutations compared with 30–40% of Asian patients.^{14–16}

Historically, the standard for EGFR mutation testing involved direct sequencing of DNA extracted from samples of tumour tissue gathered during biopsy or resection, usually in the form of formalin-fixed paraffin-embedded (FFPE) diagnostic blocks. Direct sequencing, however, has low sensitivity (ie, only detects mutations when sufficient levels of mutant DNA are present), can be complex

Open Access
Scan to access more
free content

To cite: Ellison G, Zhu G, Moulis A, et al. *J Clin Pathol* 2013;66:79–89.

and time-consuming, and is not standardised in terms of laboratory practice.^{17 18} A number of alternative methods for mutation testing have been developed and used over recent years, many with improved sensitivity and turnaround times. Another area of active research has been the evaluation of alternative sources of tumour material. As many patients with lung cancer are not identified until they have advanced disease, the procedures required to obtain a tumour biopsy sample for diagnosis may not always be possible due to co-morbidities or other reasons. Instead, cytology samples can be collected as they are adequate for the diagnosis and staging of the disease, and the procedures used to obtain these samples are generally less invasive than those used to obtain a biopsy sample. In this regard, the use of cytology samples collected for diagnostic purposes or as a result of disease complications (eg, pleural effusion (PLE)) has attracted particular attention.¹⁹

The first objective of this review was to identify and compare reported methods for *EGFR* mutation testing in patients with lung cancer. We focused on studies involving samples of biopsied or resected tumour tissue for this purpose because, in comparison with other sources of tumour DNA, such samples have traditionally been considered the standard for mutation testing. Our second objective was to evaluate published data on *EGFR* mutation testing in cytology samples when used to diagnose lung cancer in an effort to determine whether such specimens are viable alternatives to standard tumour tissue samples.

LITERATURE SEARCH METHODOLOGY

A MEDLINE database search was performed on 27 April 2012 to identify original study articles reporting on methods for *EGFR* mutation testing in patients with lung cancer. The following search terms and criteria were used: (mutation detection methods lung (All fields) AND *EGFR* (Title/Abstract) AND mutation (Title/Abstract)) OR (*EGFR* (Title/Abstract) AND mutation (Title) AND lung (Title/Abstract) AND methods (Title/Abstract)) OR (*EGFR* mutation testing lung (All fields)) OR (*EGFR* (Title/Abstract) AND mutation (Title/Abstract) AND cytology (Title/Abstract)). Search results were filtered to exclude non-English language and review articles and the titles of the remaining 284 articles were reviewed to identify potentially relevant articles. Abstracts of such articles (n=106) were reviewed and 59 studies that met one or both of the following criteria were selected for inclusion: (1) studies using 'standard' tumour tissue samples that assessed an *EGFR* mutation testing method and one or more 'comparator' methods; (2) studies reporting the use of cytology samples for *EGFR* mutation testing. Both groups excluded studies that only investigated non-TKI-sensitive *EGFR* mutations (ie, the exon 20 point mutation T790M alone) and those involving fewer than 20 samples.

EGFR MUTATION TESTING METHODS IN TUMOUR TISSUE SAMPLES

Our literature search identified 30 studies that assessed the utility of an *EGFR* mutation testing method and comparator method(s) using 20 or more tumour tissue samples (table 1). Methods were assigned into one of two broad categories: 'screening' methods that detect all mutations, including novel variants, in exons 18–21 and 'targeted' methods that detect specific, known mutations. The advantages and disadvantages of screening and targeted testing methods are summarised in table 2.

Screening methods

Table 1 includes six studies investigating the use of screening methods as alternatives to direct sequencing. In the study of Sueoka and colleagues, mutation testing results obtained by denaturing high-performance liquid chromatography (dHPLC) analysis of frozen tissue samples were consistent with those obtained by direct sequencing.²⁰ These authors reported that the analysis time for dHPLC was a quarter of that for direct sequencing. When combined with a DNA endonuclease-based technique, HPLC was shown to have 100% analytical sensitivity and negative predictive value relative to direct sequencing.²¹ A technique related to dHPLC, high-resolution melting analysis (HRMA), exhibited 100% sensitivity and 90% specificity versus direct sequencing.²² Similarly high sensitivity and specificity versus sequencing was reported for HRMA by Takano and colleagues, although this group used HRMA as a targeted method.²³ Another study utilising HRMA reported identical *EGFR* mutation frequency rates to direct sequencing.²⁴ An alternative next-generation sequencing methodology, massively parallel sequencing, was validated in a study by Querings and colleagues.²⁵ This group reported a 100% success rate of this method to detect low-frequency *EGFR* mutations compared with 89% for pyrosequencing—a non-electrophoretic sequencing technology employing luminometric detection—and 67% for direct sequencing.²⁵

Targeted methods

The results of 24 studies that assessed targeted methods for detection of common *EGFR* mutations are shown in table 1. The majority of these studies investigated the use of PCR-based methods to specifically detect exon 19 deletions, the exon 21 L858R point mutation, and, in some cases, other less common but known *EGFR* mutations.^{26–40} In these studies, which varied in their use of frozen and/or FFPE tissue samples, virtually all samples testing positive for known mutations by direct sequencing were also detected by the PCR-based screening methods under investigation. Moreover, the targeted methods detected mutations in samples that had tested negative by direct sequencing. For example, the Amplification Refractory Mutation System (ARMS)—a commonly used method that discriminates between mutated and wild-type DNA by selectively amplifying mutation-containing target sequences—detected over twice as many exon 19 deletions and L858R mutations than direct sequencing in a study by our group.³¹ However, direct sequencing detected additional mutations not designed to be identified by the specific ARMS reactions. Another method commonly used is fragment length analysis; in the study of Pan and colleagues, this method detected more exon 19 deletions than direct sequencing.³⁶ Pyrosequencing has also shown higher analytical sensitivity than direct sequencing for the two most common *EGFR* mutations; the accuracy of this method, however, was only maintained when samples contained at least 20% tumour cells.³⁸ One novel technique adapted for PCR-based mutation detection is cationic conjugated polymer (CCP)-based fluorescence resonance energy transfer (FRET).⁴⁰ This method, in which FRET probes bind to nested PCR-amplified products, detected *EGFR* mutations with comparable sensitivity (95%) and specificity (96%) to direct sequencing and RT-PCR.⁴⁰

Non-PCR-based targeted methods listed in table 1 include Smart Amplification Process (SmartAMP), a one-step mutation-detection technology that enables precise amplification of only target sequences.⁴² In a study by Hoshi and colleagues, SmartAMP and direct sequencing showed high concordance

Table 1 Studies of *EGFR* mutation testing methods using 'standard' tissue samples collected from patients with lung cancer

Reference	Mutation testing method assessed (and comparator method)	Activating mutations assessed	No. of tissue samples	Tissue sample preparation	Macro- or micro-dissected?	Ethnicity of study population	Mutation frequency (vs that with comparator method)*	Reported Se, Sp, PPV, and NPV relative to comparator
Screening methods								
Sueoka <i>et al</i> ²⁰	dHPLC (vs direct sequencing)	Exons 18–21	97 (including 16 PLE samples)	Frozen	NR	Japanese	Any mutation: 34 (35%) (vs 33 (34%))	NR
Jänne <i>et al</i> ²¹	DNA endonuclease (SURVEYOR) and HPLC (vs direct sequencing)	Exons 18–21	160 (more samples were analysed with SURVEYOR/HPLC only)	FFPE/frozen	Macro-dissected (91/117 FFPE samples only)	NR (study performed in USA)	Any mutation: 58 (36%) (vs 51 (32%))	Se, 100%; Sp, 87%; PPV, 74%; NPV, 100%
Do <i>et al</i> ²²	HRMA (vs direct sequencing)	Exons 18–21	200	FFPE	Micro-dissected	NR (study performed in Australia)	Any mutation: 118 (59%) (vs 73 (37%))	Se, 100%; Sp, 90%
Takano <i>et al</i> ²³	HRMA (vs direct sequencing)†	Exon 19 deletions and exon 21 point mutation (L858R)	66 (more samples were analysed with HRMA only)	FFPE/methanol-fixed	Micro-dissected (samples for sequencing only)	East Asian patients	Any screened mutation: 34 (52%) for FFPE and 36 (55%) for methanol-fixed (vs 37 (56%))	FFPE: Se, 92%; Sp, 100%; PPV, 100%; NPV, 90% Methanol-fixed: Se, 97%; Sp, 100%; PPV, 100%; NPV, 97%
Borràs <i>et al</i> ²⁴	HRMA (vs direct sequencing)	Exons 19–21	36	FFPE	Macro-dissected	NR (study performed in Spain)	E746–A750: 1 (2.8%) (vs 1 (2.8%)) E746–T751insA: 1 (2.8%) (vs 1 (2.8%)) L858R: 1 (2.8%) (vs 1 (2.8%)) P848L: 1 (2.8%) (vs 1 (2.8%))	NR
Querings <i>et al</i> ²⁵	Massively parallel sequencing (vs direct sequencing and pyrosequencing)	Exons 18–21	24 (including 3 cytology samples)	FFPE/frozen	NR	NR (study performed in Germany)	Any mutation: 14 (58.3%) (vs 12 (50.0%) for pyrosequencing and 9 (37.5%) for direct sequencing)	Se, 100% (vs 89% for pyrosequencing and 67% for direct sequencing)
Targeted methods								
Endo <i>et al</i> ²⁶	TaqMan PCR (vs direct sequencing)	13 mutations across exons 18–21	94 (more samples were analysed with TaqMan PCR only)	FFPE	NR	NR (study performed in Japan)	Any screened mutation: 27 (28%) (vs 26 (28%))	NR
Yatabe <i>et al</i> ²⁷	Cycleave PCR (exon 21 (L858R)) or fragment analysis (exon 19 deletion) (vs direct sequencing)	Exon 19 deletion (E746_A750) and exon 21 point mutation (L858R)	195	FFPE/frozen	Macro-dissected	NR (study performed in Japan)	E746_A750: 38 (19%) (vs 39 (20%)) L858R:33 (17%) (vs 32 (16%))	NR
Ohnishi <i>et al</i> ²⁸	Mutation-specific PCR (vs direct sequencing)	Exon 19 deletion (E746_A750) and exon 21 point mutation (L858R)	62	Frozen	NR	NR (study performed in Japan)	E746_A750: 8 (13%) (vs 8 (13%)) L858R:14 (23%) (vs 11 (18%))	NR
Asano <i>et al</i> ²⁹	Mutant-enriched PCR (vs non-enriched PCR and direct sequencing)	Exon 19 deletions and exon 21 point mutation (L858R)	108	Frozen	NR	NR (study performed in Japan)	Exon 19 deletions: 17 (16%) (vs 16 (15%) for both non-enriched PCR and direct sequencing) L858R: 20 (19%) vs (17 (16%) for both non-enriched PCR and direct sequencing)	NR
Otani <i>et al</i> ³⁰	Mutant-enriched PCR (vs non-enriched PCR and direct sequencing)	Exon 19 deletions and exon 21 point mutation (L858R)	26	Frozen	NR	NR (study performed in Japan)	Exon 19 deletions: 3 (12%) (vs 3 (11%) for both non-enriched PCR and direct sequencing) L858R: 11 (42%) (vs 6 (23%) for both non-enriched PCR and direct sequencing)	NR

Continued

Table 1 Continued

Reference	Mutation testing method assessed (and comparator method)	Activating mutations assessed	No. of tissue samples	Tissue sample preparation	Macro- or micro-dissected?	Ethnicity of study population	Mutation frequency (vs that with comparator method)*	Reported Se, Sp, PPV, and NPV relative to comparator
Ellison <i>et al</i> ³¹	ARMS (vs direct sequencing)	Exon 19 deletion (E746_A750) and exon 21 point mutation (L858R)	215	FFPE	Macro-dissected	NR	E746_A750: 9 (4%) (vs 4 (2%)) L858R: 9 (4%) (vs 4 (2%))	NR
Zhao <i>et al</i> ³²	Mutant-enriched ARMS TaqMan PCR (vs direct sequencing)	Exon 19 deletion (E746_A750) and exon 21 point mutation (L858R)	31	FFPE	NR	NR (study performed in China)	E746_A750: 5 (16%) (vs 3 (6%)) L858R: 6 (19%) (vs 5 (16%))	NR
Naoki <i>et al</i> ³³	PCR-Invader (vs DNA sequencing)	Exon 18 point mutations (G719A/C/S), exon 19 deletions, exon 20 point mutation (S768I), exon 21 point mutations (L858R and L861Q)	49 (plus 4 PLE and 1 PCE)	FFPE (tissue samples only)	Macro-dissected	Japanese	Any of the screened mutations: 28 (52%) (vs 19 (35%))	NR
Kawada <i>et al</i> ³⁴	PCR-RFLP (vs direct sequencing)	Exon 18 point mutation (G719X), exon 19 deletions and exon 21 point mutations (L858R and L861Q)	91 (plus 14 PLE, 3 PCE and 1 sputum)	Frozen	NR	NR (study performed in Japan)	Any of the screened mutations: 37 (34%) (vs 36 (33%))	NR
Molina-Vila <i>et al</i> ³⁵	Length analysis for exon 19 deletions and TaqMan assay for exon 21 point mutation (vs direct sequencing)	Exon 19 deletions and exon 21 point mutations (L858R and L861Q)	217 (includes 72 cytology samples)	FFPE/fresh	Micro-dissected	NR (study performed in Spain)	Exon 19 deletions: 25 (12%) (vs 25 (12%)) L858R: 11 (5%) (vs 11 (5%)) L861Q: 1 (0.5%) (vs 1 (0.5%))	NR
Pan <i>et al</i> ³⁶	Length analysis (exon 19 deletions) and PCR-RFLP (exon 21 (L858R)) (vs direct sequencing)	Exon 19 deletions and exon 21 point mutation (L858R)	39	NR	NR	NR (study performed in USA)	Exon 19 deletions: 15 (38%) (vs 13 (33%)) L858R: 14 (36%) (vs 12 (31%))	NR
Ikeda <i>et al</i> ³⁷	<i>In-situ</i> LAMP with ARMS (vs PCR-RFLP)	Exon 21 point mutation (L858R)	26	Paraffin-embedded	NR	NR (study performed in Japan)	L858R: 15 (58%) (vs 12 (46%))	NR
Dufort <i>et al</i> ³⁸	Pyrosequencing† (vs direct sequencing)	Exon 19 deletions and exon 21 point mutation (L858R)	58 (more samples were analysed with pyrosequencing only)	FFPE/others	NR	NR (study performed in France)	Exon 19 deletions: 11 (19%) (vs 9 (16%)) L858R: 5 (9%) (vs 4 (7%))	NR
Han <i>et al</i> ³⁹	PCR-PNA clamp (vs direct sequencing)	Exon 19 deletions, exon 20 insertions, and exon 21 point mutation (L858R and L816Q)	23 (and 41 pleural effusion samples)	FFPE	No	NR (study performed in South Korea)	Any of the screened mutations: 16 (69.6%) (vs 12 (52.2%)) for adequate biopsy specimens and 12 (52.2%) (vs 12 (52.2%)) for matched surgically resected specimens	NR
Yang <i>et al</i> ⁴⁰	PCR/CCP-based FRET (vs direct sequencing and RT-PCR)	Exon 21 point mutation (L858R)	48	FFPE	No	NR (study performed in China)	L858R: 20 (41.7%) (vs 19 (39.6%)) for direct sequencing and 21 (43.8% for RT-PCR)	Se, 95.2%; Sp, 96.3%
Hoshi <i>et al</i> ⁴¹	SmartAmp (vs direct sequencing)	Exon 18 point mutation (G719S), exon 19 deletions and exon 21 point mutation (L858R)	45	Frozen	NR	NR (study performed in Japan)	G719S: 0 (0%) (vs 0 (0%)) Exon 19 deletions: 5 (11%) (vs 5 (11%)) L858R: 5 (11%) (vs 4 (9%))	NR
Miyamae <i>et al</i> ⁴²	Conventional and PNA-clamp SmartAmp2 (vs direct sequencing)	Exon 19 deletions and exon 21 point mutation (L858R)	43	FFPE and paired frozen	NR	NR (study performed in Japan)	Exon 19 deletions: 18 (42%) (vs 12 (28%)) for frozen and FFPE L858R: 12 (28%) (vs 5 (12%)) for frozen and 11 (26%) (vs 3 (7%)) for FFPE	NR

Continued

Table 1 Continued

Reference	Mutation testing method assessed (and comparator method)	Activating mutations assessed	No. of tissue samples	Tissue sample preparation	Macro- or micro-dissected?	Ethnicity of study population	Mutation frequency (vs that with comparator method)*	Reported Se, Sp, PPV, and NPV relative to comparator
Araki <i>et al</i> ⁴³	PNA-clamp SmartAmp2 (vs direct sequencing, PNA-enriched sequencing, and SmartAmp2)	Exon 19 deletions	172	Frozen	No	Asian	Exon 19 deletions: 39 (22.7%) (vs 30 (17.4%) for direct sequencing and 38 (22.1%) for PNA-enriched sequencing and 12 (7.0%) for SmartAmp2)	NR
Kozu <i>et al</i> ⁴⁴	IHC (vs HRMA)	Exon 19 deletions and exon 21 point mutation (L858R)	577 (including 36 cytological smears)	Frozen or MFPE	No (but tumour regions selected for TMA and IHC analysis)	Japanese	Exon 19 deletions: 59 (10%) (vs 135 (23%)) L858R: 139 (24%) (vs 172 (30%))	Exon 19 deletions: Se, 42%; Sp, 100% L858R: Se, 76%; Sp, 98%
Brevet <i>et al</i> ⁴⁵	IHC (vs fragment analysis for exon 19 deletion (mutant-enriched PCR assay for discordant results) or PCR-RFLP for L858R (mass-spectrometry-based DNA analysis for discordant results))	Exon 19 deletions and exon 21 point mutation (L858R)	194	FFPE	Macro-dissected	NR (study performed in USA)	E746_A750: 22 (11%) (vs 20 (10%)) Other exon 19 deletions: 25 (13%) (vs 31 (16%)) L858R: 22 (11%) (vs 21 (11%))	E746_A750 deletion: Se, 100% Other exon 19 deletions: Se, 74% E746_A750 deletion and other exon 19 deletions: Sp, 98.8% L858R: Se, 95%; Sp, 99%
Ilie <i>et al</i> ⁴⁶	IHC (vs direct sequencing)	Exon 19 deletions	61	FFPE (direct sequencing performed on frozen samples)	No (but tumour regions selected for TMA and IHC analysis)	Caucasian	E746_A750: 12 (20%) (vs 8 (13%)) All exon 19 deletions: 13 (21%) (vs 10 (16%))	Se, 23%; NPV, 49% (calculated using results from direct sequencing plus other methods)
Kato <i>et al</i> ⁴⁷	IHC (vs direct sequencing)	Exon 19 deletion (E746_A750) and exon 21 point mutation (L858R)	70	NR	No (but tumour regions selected for TMA and IHC analysis)	Japanese	E746_A750: 9 (13%) (vs 11 (16%)) L858R: 11 (16%) (vs 12 (17%))	E746_A750: Se, 82%; Sp, 100%; PPV, 100%; NPV, 96.7% L858R: Se, 75%; Sp, 97%; PPV, 82%; NPV, 95%
Nakamura <i>et al</i> ⁴⁸	IHC (vs PNA-LNA PCR clamp/direct sequencing)	Exon 19 deletion (E746_A750) and exon 21 point mutation (L858R)	20	FFPE	No	NR (study performed in Japan)	E746_A750: 4 (20%) (vs 3 (15%)) L858R: 4 (20%) (vs 5 (25%))	Se, 92%; Sp, 100%
Simonetti <i>et al</i> ⁴⁹	IHC (vs fragment analysis, TaqMan assay, and direct sequencing)	Exon 19 deletions and exon 21 point mutations (L858R and L816Q)	78	FFPE	Micro-dissected	Caucasian	E746_A750: 17 (22%) (vs 17 (22%)) Other exon 19 deletions: 3 (4%) (vs 12 (15%)) L858R: 25 (32%) (vs 25 (32%)) L816Q: 0 (0%) (vs 2 (3%))	NR

Only studies identified by our literature search and meeting the criteria described in the Methods are listed.

*In many studies, samples were selected and/or purposely enriched to include a higher number of mutated samples; therefore, mutation frequency data should not be considered representative of the general population.

†HRMA was used as a targeted method in this study.

‡Pyrosequencing tends to be performed in a semi-targeted manner.

ARMS, Amplification Refractory Mutation System; CCP-based FRET, cationic conjugated polymer-based fluorescence resonance energy transfer; dHPLC, denaturing high-performance liquid chromatography; EGFR, epidermal growth factor receptor; FFPE, formalin-fixed paraffin-embedded; HPLC, high-performance liquid chromatography; HRMA, high-resolution melting analysis; IHC, immunohistochemistry; LAMP, loop-mediated isothermal amplification; MFPE, methanol-fixed paraffin-embedded; NPV, negative predictive value; NR, not reported; PCE, pericardial effusion; PCR-RFLP, PCR-restriction fragment length polymorphism; PLE, pleural effusion; PNA, peptide nucleic acid; PNA-LNA, PNA-locked nucleic acid; PPV, positive predictive value; Se, sensitivity; SmartAmp2, smart amplification process V.2; Sp, specificity; TMA, tissue microarray.

Table 2 Advantages and disadvantages of screening and targeted methods for *EGFR* mutation testing

	Screening methods (samples screened for all <i>EGFR</i> mutations, known and novel variants)	Targeted methods (samples analysed for known <i>EGFR</i> mutations only)
Advantages	<ul style="list-style-type: none"> ▶ All mutations, including novel mutations, may be detected (analytical sensitivity) ▶ Direct sequencing technology is widely available 	<ul style="list-style-type: none"> ▶ Less time-consuming than the screening method direct sequencing, leading to reduced turnaround times ▶ Sensitivity (limit of detection) tends to be higher than with screening methods ▶ Technology is fairly widely available
Disadvantages	<ul style="list-style-type: none"> ▶ Sensitivity tends to be lower than with targeted methods ▶ Often require enrichment of tumour cells by macro- or micro-dissection ▶ Experienced operators needed ▶ Tend to be more labour intensive and time consuming than targeted methods, leading to longer turnaround times 	<ul style="list-style-type: none"> ▶ Rare mutations not assayed for are not detected ▶ Reagents may be more expensive than for screening methods such as direct sequencing

EGFR, epidermal growth factor receptor.

when used to assess frozen clinical samples for the two most common *EGFR* mutations and the exon 18 G719S point mutation.⁴¹ A modification of this technique, peptide nucleic acid (PNA)-clamp SmartAmp2, in which oligomers of PNA (a synthetic DNA analogue) bind to wild-type DNA sequences spanning mutational hotspots, preferentially allowing for mutant DNA amplification,³⁹ has been investigated in two studies.^{42–43} One study found that PNA-clamp SmartAmp2 was more sensitive than direct sequencing at detecting the two main *EGFR* mutations using both frozen and FFPE tissue samples.⁴² Similarly, a second study reported greater sensitivity of this technique compared with direct sequencing, PNA-enriched sequencing, and conventional SmartAmp2.⁴³

Several of the studies listed in table 1 used immunohistochemistry (IHC) for the targeted mutation analysis of tissue samples.^{44–49} These studies utilised two mutant-specific rabbit monoclonal antibodies directed against the exon 19 A746_A750 deletion and L858R, and most reported high sensitivity and specificity for mutant-specific IHC versus direct sequencing and/or other comparator methods.

USE OF CYTOLOGY SAMPLES FOR *EGFR* MUTATION TESTING

In total, 33 original studies reporting the use of cytology samples for *EGFR* mutation testing were identified by our literature search (table 3). Commonly tested cytology samples included tissue samples collected during diagnosis (eg, fine needle aspirate (FNA) samples acquired via minimally invasive biopsy procedures, which often contain high proportions of tumour cells) or liquid-based samples obtained from patients experiencing common complications of lung cancer (eg, PLE, which often have low tumour cell content). Use of sensitive mutation testing methods is warranted when cytology samples with low tumour content are used. In two separate studies, *EGFR* mutations detected by mutant-enriched PCR in some PLE samples were not detected by non-enriched assays.^{29–30} Similarly, the sensitive ARMS technique has been shown to detect mutations in PLE samples not identified via direct sequencing.⁵¹ Interestingly, the detection rate of *EGFR* mutations with direct sequencing improved from 45% when using genomic DNA to 67% when using tumour-derived RNA isolated from PLE samples as an alternative source.⁵² ARMS was also more sensitive than direct sequencing in studies utilising transbronchial FNA.⁵³ Our search showed that the use of FNA for detection of *EGFR* mutations has been relatively widely investigated (table 3). Several FNA-generating techniques used for the diagnosis and staging of lung cancers have attracted

particular interest in this regard: endobronchial ultrasound-guided fine needle aspiration (EBUS-FNA), trans-oesophageal ultrasound-guided fine needle aspiration (EUS-FNA), and CT-guided FNA. Cytology samples obtained via these techniques were successfully assessed for *EGFR* mutations using direct sequencing.^{54–55} Other studies have reported the successful use of EBUS-FNA and/or EUS-FNA samples with real-time PCR,^{56–57} COLD-PCR,⁵⁸ PNA-locked nucleic acid (LNA) PCR clamp,⁵⁹ or loop-hybrid mobility shift assay.⁶⁰

DISCUSSION AND FUTURE PERSPECTIVES

A variety of methods have been employed as potential alternatives to the historical standard for *EGFR* mutation testing, direct sequencing. In practice, the choice of testing method should be based primarily on the nature of the sample to be tested including tumour content (particularly for cytology material), the testing laboratory's expertise and available equipment, and whether detection of known activating *EGFR* mutations only is considered sufficient (figure 1).

Reflecting its position as the historical standard, direct sequencing was used as the comparator method in many of the studies identified by our search. The variability observed between studies when comparing sequencing to other mutation testing methods may be due to technical differences, such as primers or reagents used by individual laboratories. Perhaps the primary limitation of direct sequencing is its low sensitivity; indeed, a mutation should generally be present in approximately 20% of all DNA in a sample to be reliably detected by this method.^{78–79} In our experience, the approximate tumour content of lung tissue samples can range from 5 to 100%. Therefore, a limit of detection of 20% means that direct sequencing may offer insufficient sensitivity.⁸⁰ Preparation of samples by macro-dissection or laser capture micro-dissection prior to DNA extraction, however, can enrich tumour cell content and thereby increase the utility of sequencing as a routine pre-treatment test.⁸¹ While relatively cost-effective from a reagent perspective compared with targeted methods,⁸² these preparatory enrichment methods are labour intensive and time consuming and provide a relatively marginal improvement. Alternative screening methods to direct sequencing include dHPLC and HRMA. Although dHPLC appears to have higher analytical sensitivity than direct sequencing,²⁰ dHPLC requires extra processing steps after PCR amplification and the use of expensive instrumentation.²² HRMA has been proposed as an alternative, and is able to detect mutant genes at levels of 2.5–10%.^{22–24} HRMA is relatively inexpensive; however, samples testing positive by HRMA must then be analysed by direct sequencing to

Table 3 Studies of *EGFR* mutation testing methods using cytology samples collected from patients with lung cancer

Reference	Cytology samples (no. of samples for mutation analysis (fail data if available))	Method(s) of <i>EGFR</i> mutation testing assessed	Authors' conclusions on use of cytology samples for <i>EGFR</i> mutation testing
Asano <i>et al</i> ²⁹	Cell-free PLE (n=20), CT-guided needle lung biopsies (n=18)	Mutant-enriched PCR versus non-enriched PCR and direct sequencing	Mutant-enriched PCR detected <i>EGFR</i> alterations that were not identified with a non-enriched assay
Fassina <i>et al</i> ⁶¹	TTNA samples (n=77)	HRMA versus direct sequencing	HRMA of TTNA samples was accurate, fast, easy, cheap, and reliable for the detection of common <i>EGFR</i> mutations
Hlinkova <i>et al</i> ⁶²	Cytological samples obtained by endobronchial brushing (n=53)	HRMA versus direct sequencing (with mutant-enriched PCR if <25% tumour cells)	HRMA in combination with mutant-enriched PCR is a sensitive method for mutation detection in cytology samples
Horiike <i>et al</i> ⁵³	Transbronchial FNA (n=93 (10 fails (11%) with direct sequencing; 0 fails with Scorpion ARMS))	Scorpion ARMS versus direct sequencing	Both methods detected <i>EGFR</i> mutations in transbronchial FNA samples although Scorpion ARMS was more sensitive
Kawahara <i>et al</i> ⁶³	PLE (n=21), CSF (n=2), and ascites (n=1)	Immunocytochemistry versus PNA-LNA PCR clamp	<i>EGFR</i> mutations were detected in PLE and CSF with 100% sensitivity using antibodies specific for the exon 19 deletion E746_A750 and the exon 21 point mutation L858R
Kimura <i>et al</i> ⁶⁴	Cell-free PLE (n=43)	Direct sequencing	DNA in PLE can be used to detect <i>EGFR</i> mutations
Kimura <i>et al</i> ⁵¹	Cell-free PLE (n=24)	Scorpion ARMS versus direct sequencing	DNA in PLE can be used to detect <i>EGFR</i> mutations. Scorpion ARMS was more sensitive than direct sequencing
Kozu <i>et al</i> ⁴⁴	Imprint cytological smears from fresh-cut surface of resected tumour specimens (n=36)	HRMA versus IHC	(Results of cytology sample analyses were combined with those of 541 tissue specimens (see table 2))
Lim <i>et al</i> ⁶⁵	FNA (n=29)	Whole genome amplification followed by direct sequencing	<i>EGFR</i> mutations were identified using direct sequencing of whole genome-amplified genomic DNA from low-volume FNA samples
Lozano <i>et al</i> ⁶⁶	Primary lung tumour FNA (n=68), metastatic lymph node FNA (n=10), bone metastases FNA (n=3), left adrenal metastasis FNA (n=1), PLE (n=6), PCE (n=1), and bronchoalveolar lavage (n=1)	Direct sequencing	Assessment of <i>EGFR</i> mutation in cytology samples is feasible and comparable with biopsy results
Nakajima <i>et al</i> ⁶⁰	EBUS-TBNA samples from metastatic lymph nodes (n=43)	Loop-hybrid mobility shift assay confirmed by direct sequencing	<i>EGFR</i> mutations can easily be detected in metastatic lymph nodes samples by EBUS-TBNA
Oshita <i>et al</i> ⁶⁷	Cytology samples obtained by transbronchial abrasion (n=52) (2 fails (4%))	Loop-hybrid mobility shift assay	Assessment of <i>EGFR</i> mutations in cytological samples is feasible and comparable with biopsy results
Otani <i>et al</i> ³⁰	Biopsy needle wash fluid (n=26)	Mutant-enriched PCR versus non-enriched PCR versus direct sequencing	<i>EGFR</i> mutations can be detected in the wash fluid of CT-guided biopsy needles
Rekhtman <i>et al</i> ⁶⁸	Transbronchial/transthoracic FNA (n=67), extrathoracic FNA (n=29), PLE (n=29), and bronchial brush/wash (n=3) (2 failures (2%))	Length analysis and PCR-RFLP	<i>EGFR</i> analysis is feasible in routinely processed cytology samples
Savic <i>et al</i> ⁶⁹	Transbronchial FNA (n=35), PLE (n=16), bronchial washing (n=15), bronchial brushes (n=13), and bronchoalveolar lavage (n=5)	PCR-direct sequencing	<i>EGFR</i> analyses are applicable to cytology specimens
Schuurbiers <i>et al</i> ⁵⁴	EBUS-/EUS-FNA samples (n=35 (8 fails (23%))	Direct sequencing	Molecular analysis for <i>EGFR</i> mutations can be performed routinely in EBUS-/EUS-FNA samples
Soh <i>et al</i> ⁵⁰	Cell-free PLE (n=61)	Direct sequencing versus mutant-enriched PCR versus non-enriched PCR versus PNA-LNA PCR-clamp	Some discrepancies between the results of the four assays were noted. Mutant-enriched PCR detected the most mutations
Takano <i>et al</i> ²³	Bronchial brushing/washing (n=43), PLE (n=40), transbronchial FNA (n=9), PCE (n=8), superficial lymph node FNA (n=7), tumour FNA (n=6), and sputum (n=4)	HRMA versus direct sequencing	Exon 19 deletions and the exon 21 point mutation L858R can likely be detected from archived Papanicolaou-stained cytology slides with sensitivity of ca. 90% and specificity of ca. 100%
van Eijk <i>et al</i> ⁵⁶	EBUS-TBNA/EUS-FNA samples (numerous samples from 43 patients)	Real-time PCR with hydrolysis probes	All mutations detected in matched histological samples were also identified in the cytology samples
Yasuda <i>et al</i> ⁷⁰	ELF (n=23)	PNA-LNA PCR clamp	Sensitivity for detecting mutations in ELF was 58%
Zhang <i>et al</i> ⁷¹	PLE cells and matched cell-free PLE (n=26)	Mutant-enriched PCR versus direct sequencing	Direct sequencing may miss a significant proportion of mutations in PLE samples. Mutant-enriched PCR may be more reliable
Smits <i>et al</i> ⁷²	Cytology and FFPE samples (n=816; 719 samples had interpretable result)	Direct sequencing or HRMA	(Results of cytology sample analyses were combined with those of FFPE specimens)
Tsai <i>et al</i> ⁷³	PLE (n=78)	IHC versus direct sequencing	<i>EGFR</i> mutations were detected in PLE with 71% and 88% sensitivity using antibodies specific for the exon 19 deletion E746_A750 and the exon 21 point mutation L858R, respectively

Continued

Table 3 Continued

Reference	Cytology samples (no. of samples for mutation analysis (fail data if available))	Method(s) of <i>EGFR</i> mutation testing assessed	Authors' conclusions on use of cytology samples for <i>EGFR</i> mutation testing
Navani <i>et al</i> ⁵⁷	EBUS-TBNA samples (n=774)	ARMS or MassARRAY	Correlation of TKI response rate with <i>EGFR</i> mutation status was comparable when determined by IHC and direct sequencing (67% vs 72%) EBUS-TBNA cytology samples are suitable for <i>EGFR</i> analysis
Aisner <i>et al</i> ⁷⁴	Cytology cell blocks, including FNA of primary and metastatic lung lesions and exfoliative cytology specimens (n=42)	PCR-sequencing	Cell block specimens provide an alternative DNA source to surgical specimens for <i>EGFR</i> analysis
Zhuang <i>et al</i> ⁵⁵	CT-guided FNA biopsy (n=43)	Direct sequencing	CT-guided FNA biopsy is a feasible and safe method to provide samples for <i>EGFR</i> analysis
Santis <i>et al</i> ⁵⁸	EBUS-TBNA lymph node samples (n=131; successful analysis of 126 samples)	COLD-PCR	EBUS-TBNA samples provide sufficient tumour material for <i>EGFR</i> mutation analysis COLD-PCR is a robust screening assay for <i>EGFR</i> mutations
Malapelle <i>et al</i> ⁷⁵	LBC (n=42)	Direct sequencing	LBC samples can be used for <i>EGFR</i> mutation analysis; however, direct sequencing requires micro-dissection to provide sufficient sample DNA
Betz <i>et al</i> ⁷⁶	Romanowsky-stained direct cytology smears (n=33)	Direct sequencing	Following micro-dissection, direct smears can be used as a specimen source for <i>EGFR</i> analysis when cell blocks exhibit insufficient cellularity
Cho <i>et al</i> ⁷⁷	Body fluid specimen (n=32: pleural fluids (n=29), CSF (n=1), pericardial (n=1), and ascites (n=1))	Direct sequencing	Combined direct sequencing and cytological analysis might be clinically useful and sensitive for the detection of <i>EGFR</i> mutations
Tsai <i>et al</i> ⁵²	PLE (n=150)	Direct sequencing of cell-derived RNA versus genomic DNA	Sequencing of RNA improves sensitivity for <i>EGFR</i> mutation detection in PLE samples compared with genomic DNA
Lozano <i>et al</i> ⁶⁶	Cytology samples (n=150: Papanicolaou smears (n=120), Fresh/liquid (n=14), cell block (n=10), ThinPrep tests (n=6))	Direct sequencing	<i>EGFR</i> analysis using cytological samples is feasible and comparable with biopsy results
Nakajima <i>et al</i> ⁵⁹	EBUS-TBNA metastatic lymph node samples (n=156)	PNA-LNA PCR clamp	EBUS-TBNA samples can be used for multi-gene mutational analysis

Only studies identified by our literature search and meeting the criteria described in the Methods are listed.

ARMS, Amplification Refractory Mutation System; COLD-PCR, coamplification at lower denaturation temperature PCR; CSF, cerebrospinal fluid; EBUS-FNA, endobronchial ultrasound-guided fine needle aspiration; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; *EGFR*, epidermal growth factor receptor; ELF, epithelial lining fluid; EUS-FNA, trans-oesophageal ultrasound scanning with fine needle aspiration; FFPE, formalin-fixed paraffin-embedded; FNA, fine needle aspirate; HRMA, high-resolution melting analysis; IHC, immunohistochemistry; LBC, liquid-based cytology; MassARRAY, matrix-assisted laser desorption/ionisation mass spectroscopy; PCE, pericardial effusion; PCR-RFLP, PCR-restriction fragment length polymorphism assay; PLE, pleural effusion; PNA-LNA, peptide nucleic acid-locked nucleic acid; TKI, tyrosine kinase inhibitor; TTNA, trans-thoracic needle aspiration.

ensure that mutations are properly identified.²⁴ This can be problematic when levels of mutant DNA do not permit analysis by direct sequencing.

Targeted methods, which detect specific mutations only, tend to be more sensitive in terms of limit of detection than screening techniques. ARMS, for example, is a simple PCR-based testing method shown to be more sensitive and robust than

direct sequencing for the assessment of common *EGFR* mutations in FFPE tumour tissue.³¹ One other targeted method to be validated is fragment length analysis. While fragment length analysis is used widely in practice, it can only detect insertions or deletions and does not allow detection of point mutations in *EGFR*. Compared with some other methods, mutant-specific IHC is fast, cost-effective, and can be performed in most

Figure 1 Factors determining the choice of *EGFR* mutation testing method.

pathology laboratories.⁴⁴ IHC, however, has not been widely adopted for *EGFR* mutation analysis amid concerns that it is not as sensitive or as specific as DNA-based molecular techniques. A study comparing *EGFR* mutation testing between 15 centres in France (the Evaluation of the *EGFR* Mutation Status for the Administration of *EGFR*-TKIs in Non-Small Cell Lung Carcinoma (ERMETIC) project) suggested that detection accuracy is dependent upon sample quality rather than the sequencing method used, highlighting the importance of good sample collection and processing techniques.⁸³ For poor quality samples, care must be taken to ensure the selection of tumour cells, in addition to the DNA concentration, as test results are frequently dependent on both these parameters.

The availability of targeted methods with high sensitivity offers the potential for accurate, rapid, and high-throughput analysis of clinical samples. The main theoretical drawback of these techniques is their inability to detect all activating *EGFR* mutations. The majority of clinical evidence to date robustly supports the use of *EGFR* TKIs in patients with the two most common activating mutations in *EGFR* (exon 19 deletions and the L858R point mutation in exon 21), and most targeted methods are specifically designed to detect these mutations. However, clinical data on less common mutations are emerging and further research is required to fully inform predictable outcomes on *EGFR* TKIs, aided by the use of sample micro dissection followed by screening methods, to ensure identification of all known mutations.¹⁸ While targeted methods can fail to detect some of the rare mutations which are detected by screening, it is anticipated that rare mutations demonstrated to have therapeutic implications will subsequently be included in targeted screening approaches, thus ensuring all patients will benefit from the appropriate therapy. Both screening and targeted methods have been used to identify *EGFR* mutations in clinical trials of *EGFR* TKIs in patients with advanced NSCLC.^{6–10 14–16 84} These trials were not identified by our search due to our focus on method comparison studies. In practice, laboratories can opt to use commercially available kits or to develop their own tests. Testing kits such as those utilising the ARMS method have the advantages of being validated, ready for use and quality controlled. Laboratory-developed tests, many of which were identified by our search, may be less expensive, but take time to develop and validate and may have limited quality control. If procedures for *EGFR* mutation testing are not established at a local level, use of one of a number of global testing laboratories may be considered. Such laboratories use a variety of methods for *EGFR* mutation testing including commercially available kits and laboratory-developed tests.

Our literature search confirmed that cytology samples are suitable testing material for *EGFR* mutation testing and that detection rates appear to be as high as those obtained with traditional tissue samples. The suitability of cytology samples for routine clinical practice has been recognised in published recommendations for *EGFR* mutation testing.⁸⁵ Of note, in the recent study of Goto and colleagues, published after we performed our literature search, five different *EGFR* testing methods (PCR-Invader, PNA-LNA-PCR clamp, PCR-direct sequencing, cycleave PCR, and ARMS) showed comparable performance in the assessment of tissue and cytology samples. Furthermore, the concordance between matched tumour and cytology samples was extremely high.⁸⁶

There is a growing trend toward the extensive molecular characterisation of tumours so that the most appropriate therapy can be selected. This is exemplified in the Biomarker-integrated Approaches of Targeted Therapy for Lung cancer Elimination trial,

in which patients are adaptively randomised to various treatments based on relevant molecular biomarkers.⁸⁷ This approach has been made possible by the availability of methods such as Sequenom MassArray,⁸⁸ SNaPshot,^{89–91} and arrays of mutation-specific PCR assays (eg, qBiomarker Somatic Mutation PCR Array), and through the use of next-generation sequencing. These methods can rapidly and sensitively detect many known mutations in a relatively small amount of DNA. Using such gene panel approaches will no doubt increase our knowledge of pharmacogenetic predictive biomarkers and therefore improve patient outcomes by ensuring that each patient is given a treatment with the most likely chance of success. To date, no point-of-care devices are available for *EGFR* mutation testing; the future development of such devices would be welcome and would help ensure that treatment is not delayed while test results are awaited.

CONCLUSIONS

The *EGFR* mutation testing landscape is varied and includes a number of screening and targeted methods. Each method has its own benefits and limitations and the choice of method used in practice should be made according to the nature of the sample to be tested, the testing laboratory's expertise and access to equipment, and whether detection of known activating *EGFR* mutations only or all possible mutations is required. Cytology samples can be used to reliably detect *EGFR* mutations. Mutation detection rates with cytology samples are comparable with those achieved with traditional tissue samples obtained by biopsy or resection.

Key messages

- ▶ The development of targeted *EGFR* mutation testing methods and commercially available test kits has enabled sensitive, rapid and robust analysis of clinical samples from patients with NSCLC.
- ▶ The use of screening methods, either used alone or in conjunction with targeted methods, enables the detection of more rare and novel *EGFR* mutations.
- ▶ Evidence published to date suggests cytology samples (including fine needle aspirate and pleural effusion) are viable alternatives for mutation testing when tumour tissue samples are not available.
- ▶ The choice of method used in practice should be made according to the nature of the sample to be tested, the testing laboratory's expertise and access to equipment, and whether detection of known activating *EGFR* mutations only or all possible mutations is required.

Acknowledgements Medical writing support was provided by Rick Fleming, PhD, CMPP and Annette Smith, PhD of Complete Medical Communications, and was funded by AstraZeneca.

Contributors All authors made substantial contributions to the conception, design and execution of the review and interpretation of the data. All authors contributed to the intellectual content of the manuscript, reviewed and critically revised it and approved of the final submitted version.

Funding This study, including design, collection/analysis/interpretation of data, writing, and decision to submit this manuscript for publication was supported by AstraZeneca.

Competing interests GE, GZ, AM, SD, GS, and RM are full-time employees of AstraZeneca. GE, SD, GS, and RM are holders of AstraZeneca shares.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- 1 Ferlay J, Shin HR, Bray F, *et al.* Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893–917.
- 2 Azzoli CG, Baker S Jr, Temin S, *et al.* American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. *J Clin Oncol* 2009;27:6251–66.
- 3 Lynch TJ, Bell DW, Sordella R, *et al.* Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–39.
- 4 Paez JG, Jänne PA, Lee JC, *et al.* EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497–500.
- 5 Pao W, Miller V, Zakowski M, *et al.* EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA* 2004;101:13306–11.
- 6 Maemondo M, Inoue A, Kobayashi K, *et al.* Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380–8.
- 7 Mitsudomi T, Morita S, Yatabe Y, *et al.* Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121–8.
- 8 Mok TS, Wu Y-L, Thongprasert S, *et al.* Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947–57.
- 9 Rosell R, Carcereny E, Gervais R, *et al.* Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EORTC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012;13:239–46.
- 10 Zhou C, Wu Y-L, Chen G, *et al.* Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011;12:735–42.
- 11 Han JY, Park K, Kim SW, *et al.* First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in never-smokers with adenocarcinoma of the lung. *J Clin Oncol* 2012;30:1122–8.
- 12 Keedy VL, Temin S, Somerfield MR, *et al.* American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. *J Clin Oncol* 2011;29:2121–7.
- 13 Sharma SV, Bell DW, Settleman J, *et al.* Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer* 2007;7:169–81.
- 14 Cortes-Funes H, Gomez C, Rosell R, *et al.* Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. *Ann Oncol* 2005;16:1081–6.
- 15 Tokumo M, Toyooka S, Kiura K, *et al.* The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. *Clin Cancer Res* 2005;11:1167–73.
- 16 Yoshida K, Yatabe Y, Park JY, *et al.* Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. *J Thorac Oncol* 2007;2:22–8.
- 17 Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. *J Clin Oncol* 2008;26:983–94.
- 18 Penzel R, Sers C, Chen Y, *et al.* EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. *Virchows Arch* 2011;458:95–8.
- 19 da Cunha Santos G, Saiegh MA, Geddie W, *et al.* EGFR gene status in cytological samples of non-small cell lung carcinoma: controversies and opportunities. *Cancer Cytopathol* 2011;119:80–91.
- 20 Sueoka N, Sato A, Eguchi H, *et al.* Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. *J Cancer Res Clin Oncol* 2007;133:93–102.
- 21 Jänne PA, Borrás AM, Kuang Y, *et al.* A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. *Clin Cancer Res* 2006;12:751–8.
- 22 Do H, Krypuy M, Mitchell PL, *et al.* High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. *BMC Cancer* 2008;8:142.
- 23 Takano T, Ohe Y, Tsuta K, *et al.* Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. *Clin Cancer Res* 2007;13:5385–90.
- 24 Borrás E, Jurado I, Hernan I, *et al.* Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. *BMC Cancer* 2011;11:406.
- 25 Querings S, Altmüller J, Ansén S, *et al.* Benchmarking of mutation diagnostics in lung lung cancer specimens. *PLoS One* 2011;6:e19601.
- 26 Endo K, Konishi A, Sasaki H, *et al.* Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. *Lung Cancer* 2005;50:375–84.
- 27 Yatabe Y, Hida T, Horio Y, *et al.* A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. *J Mol Diagn* 2006;8:335–41.
- 28 Ohnishi H, Ohtsuka K, Ooide A, *et al.* A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. *Diagn Mol Pathol* 2006;15:101–8.
- 29 Asano H, Toyooka S, Tokumo M, *et al.* Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. *Clin Cancer Res* 2006;12:43–8.
- 30 Otani H, Toyooka S, Soh J, *et al.* Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients. *J Thorac Oncol* 2008;3:472–6.
- 31 Ellison G, Donald E, McWalter G, *et al.* A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. *J Exp Clin Cancer Res* 2010;29:132.
- 32 Zhao J, Zhao J, Huang J, *et al.* A novel method for detection of mutation in epidermal growth factor receptor. *Lung Cancer* 2011;74:226–32.
- 33 Naoki K, Soejima K, Okamoto H, *et al.* The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. *Int J Clin Oncol* 2011;16:335–44.
- 34 Kawada I, Soejima K, Watanabe H, *et al.* An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. *J Thorac Oncol* 2008;3:1096–103.
- 35 Molina-Vila MA, Bertran-Alamillo J, Reguart N, *et al.* A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. *J Thorac Oncol* 2008;3:1224–35.
- 36 Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. *J Mol Diagn* 2005;7:396–403.
- 37 Ikeda S, Takabe K, Inagaki M, *et al.* Detection of gene point mutation in paraffin sections using *in situ* loop-mediated isothermal amplification. *Pathol Int* 2007;57:594–9.
- 38 Dufort S, Richard MJ, Lantuejoul S, *et al.* Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. *J Exp Clin Cancer Res* 2011;30:57.
- 39 Han HS, Lim SN, An JY, *et al.* Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. *J Thorac Oncol* 2012;7:355–64.
- 40 Yang Q, Qiu T, Wu W, *et al.* Simple and sensitive method for detecting point mutations of epidermal growth factor receptor using cationic conjugated polymers. *ACS Appl Mater Interfaces* 2011;3:4539–45.
- 41 Hoshi K, Takakura H, Mitani Y, *et al.* Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. *Clin Cancer Res* 2007;13:4974–83.
- 42 Miyamae Y, Shimizu K, Mitani Y, *et al.* Mutation detection of epidermal growth factor receptor and KRAS genes using the Smart Amplification Process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. *J Mol Diagn* 2010;12:257–64.
- 43 Araki T, Shimizu K, Nakamura T, *et al.* Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma. *Oncol Rep* 2011;26:1213–19.
- 44 Kozu Y, Tsuta K, Kohno T, *et al.* The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. *Lung Cancer* 2011;73:45–50.
- 45 Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. *J Mol Diagn* 2010;12:169–76.
- 46 Ilie MI, Hofman V, Bonnetaud C, *et al.* Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. *Virchows Arch* 2010;457:483–95.
- 47 Kato Y, Peled N, Wynes MW, *et al.* Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. *J Thorac Oncol* 2010;5:1551–8.
- 48 Nakamura H, Mochizuki A, Shinmyo T, *et al.* Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. *Anticancer Res* 2010;30:5233–7.
- 49 Simonetti S, Molina MA, Queralt C, *et al.* Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. *J Transl Med* 2010;8:135.

- 50 Soh J, Toyooka S, Aoe K, *et al.* Usefulness of *EGFR* mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. *Int J Cancer* 2006;119:2353–8.
- 51 Kimura H, Fujiwara Y, Sone T, *et al.* High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. *Cancer Sci* 2006;97:642–8.
- 52 Tsai T-H, Su K-Y, Wu S-G, *et al.* RNA is favourable for analysing *EGFR* mutations in malignant pleural effusion of lung cancer. *Eur Respir J* 2012;39:677–84.
- 53 Horiike A, Kimura H, Nishio K, *et al.* Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. *Chest* 2007;131:1628–34.
- 54 Schuurbiers OCJ, Looijen-Salamon MG, Ligtenberg MJL, *et al.* A brief retrospective report on the feasibility of epidermal growth factor receptor and *KRAS* mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. *J Thorac Oncol* 2010;5:1664–7.
- 55 Zhuang Y-P, Wang H-Y, Shi M-Q, *et al.* Use of CT-guided fine needle aspiration biopsy in epidermal growth factor receptor mutation analysis in patients with advanced lung cancer. *Acta Radiol* 2011;52:1083–7.
- 56 van Eijk R, Licht J, Schrumpf M, *et al.* Rapid *KRAS*, *EGFR*, *BRAF* and *PIK3CA* mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. *PLoS One* 2011;6:e17791.
- 57 Navani N, Brown JM, Nankivell M, *et al.* Suitability of EBUS-TBNA specimens for subtyping and genotyping of NSCLC: a multi-centre study of 774 patients. *Am J Respir Crit Care Med* 2012;185:1316–22.
- 58 Santis G, Angell R, Nickless G, *et al.* Screening for *EGFR* and *KRAS* mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. *PLoS One* 2011;6:e25191.
- 59 Nakajima T, Yasufuku K, Nakagawara A, *et al.* Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. *Chest* 2011;140:1319–24.
- 60 Nakajima T, Yasufuku K, Suzuki M, *et al.* Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. *Chest* 2007;132:597–602.
- 61 Fassina A, Gazziero A, Zardo D, *et al.* Detection of *EGFR* and *KRAS* mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. *J Clin Pathol* 2009;62:1096–102.
- 62 Hlinkova K, Babál P, Berzinec P, *et al.* Rapid and efficient detection of *EGFR* mutations in problematic cytologic specimens by high-resolution melting analysis. *Mol Diagn Ther* 2011;15:21–9.
- 63 Kawahara A, Azuma K, Sumi A, *et al.* Identification of non-small-cell lung cancer with activating *EGFR* mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. *Lung Cancer* 2011;74:35–40.
- 64 Kimura H, Fujiwara Y, Sone T, *et al.* *EGFR* mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. *Br J Cancer* 2006;95:1390–5.
- 65 Lim EH, Zhang S-L, Li J-L, *et al.* Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of *EGFR*, *KRAS*, *p53*, and *CMET* mutations in advanced-stage non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2009;4:12–21.
- 66 Lozano MD, Zulueta JJ, Echeveste JJ, *et al.* Assessment of epidermal growth factor receptor and k-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. *Oncologist* 2011;16:877–85.
- 67 Oshita F, Matsukuma S, Yoshihara M, *et al.* Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing *EGFR* gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. *Br J Cancer* 2006;95:1070–5.
- 68 Rekhman N, Brandt SM, Sigel CS, *et al.* Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of *EGFR* and *KRAS* molecular testing. *J Thorac Oncol* 2011;6:451–8.
- 69 Savic S, Tapia C, Grilli B, *et al.* Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. *Br J Cancer* 2008;98:154–60.
- 70 Yasuda H, Soejima K, Nakayama S, *et al.* Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. *Lung Cancer* 2011;72:32–8.
- 71 Zhang X, Zhao Y, Wang M, *et al.* Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. *Lung Cancer* 2008;60:175–82.
- 72 Smits AJ, Kummer JA, Hinrichs JW, *et al.* *EGFR* and *KRAS* mutations in lung carcinomas in the Dutch population: increased *EGFR* mutation frequency in malignant pleural effusion of lung adenocarcinoma. *Cell Oncol (Dordr)* 2012;35:189–96.
- 73 Tsai T-H, Wu S-G, Chang Y-L, *et al.* Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. *J Thorac Oncol* 2012;7:993–1000.
- 74 Aisner DL, Deshpande C, Baloch Z, *et al.* Evaluation of *EGFR* mutation status in cytology specimens: an institutional experience. *Diagn Cytopathol* 2011;doi: 10.1002/dc.21851.
- 75 Malapelle U, de Rosa N, Rocco D, *et al.* *EGFR* and *KRAS* mutations detection on lung cancer liquid-based cytology: a pilot study. *J Clin Pathol* 2012;65:87–91.
- 76 Betz BL, Roh MH, Weigelin HC, *et al.* The application of molecular diagnostic studies interrogating *EGFR* and *KRAS* mutations to stained cytologic smears of lung carcinoma. *Am J Clin Pathol* 2011;136:564–71.
- 77 Cho MC, Choi CM, Kim S, *et al.* Direct sequencing in cytological specimens as a useful strategy for detecting *EGFR* mutations in non-small cell lung cancer patients. *Clin Chem Lab Med* 2011;50:565–72.
- 78 Li J, Wang L, Mamon H, *et al.* Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. *Nat Med* 2008;14:579–84.
- 79 Ogino S, Kawasaki T, Brahmandam M, *et al.* Sensitive sequencing method for *KRAS* mutation detection by Pyrosequencing. *J Mol Diagn* 2005;7:413–21.
- 80 Coghlin CL, Smith LJ, Bakar S, *et al.* Quantitative analysis of tumor in bronchial biopsy specimens. *J Thorac Oncol* 2010;5:448–52.
- 81 Chowdhuri SR, Xi L, Pham TH, *et al.* *EGFR* and *KRAS* mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. *Mod Pathol* 2012;25:548–55.
- 82 Whitehall V, Tran K, Umapathy A, *et al.* A multicenter blinded study to evaluate *KRAS* mutation testing methodologies in the clinical setting. *J Mol Diagn* 2009;11:543–52.
- 83 Beau-Faller M, Degeorges A, Rolland E, *et al.* Cross-validation study for epidermal growth factor receptor and *KRAS* mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the *EGFR* mutation status for the administration of *EGFR*-TKIs in non-small cell lung carcinoma [ERMETIC] project—part 1). *J Thorac Oncol* 2011;6:1006–15.
- 84 Rosell R, Ichinose Y, Taron M, *et al.* Mutations in the tyrosine kinase domain of the *EGFR* gene associated with gefitinib response in non-small-cell lung cancer. *Lung Cancer* 2005;50:25–33.
- 85 Marchetti A, Normanno N, AIOM-SIAPEC-IAP, *et al.* Recommendations for mutational analysis of *EGFR* in lung carcinoma. *Pathologica* 2010; 102:119–22.
- 86 Goto K, Satouchi M, Ishii G, *et al.* An evaluation study of *EGFR* mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. *Ann Oncol* 2012; 2012;23:2914–9.
- 87 Kim ES. The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discov* 2011;1:43–51.
- 88 MacConaill LE, Campbell CD, Kehoe SM, *et al.* Profiling critical cancer gene mutations in clinical tumor samples. *PLoS One* 2009;4:e7887.
- 89 Dias-Santagata D, Akhavanfar S, David SS, *et al.* Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med* 2010;2:146–58.
- 90 Su Z, Dias-Santagata D, Duke M, *et al.* A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. *J Mol Diagn* 2011;13:74–84.
- 91 Sequist LV, Heist RS, Shaw AT, *et al.* Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. *Ann Oncol* 2011;22:2616–24.